Cookies on this site

Measles is a highly infectious viral disease which can lead to serious complications. In high income regions of the world such as Western Europe, it causes death in at least 1 in 5000 cases, but as many as 1 in 100 will die in the poorest regions of the world.

Worldwide, measles is still a major cause of death, especially among children in resource-poor countries. In 2011, 158,000 people died of measles – an average of 432 every day. However, over the last twenty years vaccination has dramatically reduced the number of deaths from measles. Since 1990 (when measles killed 872,000 people), over one in 5 of all child deaths averted have been due to measles vaccination.

In the short film below, experts talk about measles and its complications, and the importance of the MMR vaccine.

Read more about the symptoms, how it is passed on and how the MMR vaccine protects people on the Vaccine Knowledge Project website.

Similar stories

New $46M Grant Allows the University of Oxford and Boston Children’s Hospital to Lead Genetic Medicines Hub within ARIA Ecosystem

The University of Oxford and Boston Children’s Hospital, with collaboration from The Jackson Laboratory and N=1 Collaborative, have been selected to establish a new Genetic Medicines Hub, one of six research hubs within the Aligning Research to Impact Autism (ARIA) ecosystem.

Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.

University of Oxford and BIIE launch collaboration in translational immune engineering

Researchers from the Department of Paediatrics at the University of Oxford and the Botnar Institute of Immune Engineering (BIIE) came together in Oxford last week for the inaugural scientific meeting of the new Basel–Oxford Centre for Translational Immune Engineering for Child and Adolescent Health (CTIE). The CTIE is a new collaboration between the Department of Paediatrics and the BIIE in Basel, Switzerland, designed to accelerate the translation of advances in immune engineering into new diagnostics, vaccines, therapeutics and other approaches to prevent and treat disease. Its focus is on improving the health of children and adolescents in low- and middle-income countries.

Oxford-led newborn screening pilot expanded to include all babies in England

Every newborn baby in England will be screened for spinal muscular atrophy (SMA), following the expansion of a pioneering University of Oxford-led pilot that introduced the country’s first routine test for the condition.

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Scientists in the Department of Paediatrics discover antibody combinations that block over 90% of malaria parasite growth

In an important discovery for the next-generation of malaria vaccines, University of Oxford researchers in the Department of Paediatrics, in collaboration with the Scripps Institute, have identified how antibodies can be over 90% effective at preventing malaria parasites from growing in certain combinations.

Similar stories

New $46M Grant Allows the University of Oxford and Boston Children’s Hospital to Lead Genetic Medicines Hub within ARIA Ecosystem

The University of Oxford and Boston Children’s Hospital, with collaboration from The Jackson Laboratory and N=1 Collaborative, have been selected to establish a new Genetic Medicines Hub, one of six research hubs within the Aligning Research to Impact Autism (ARIA) ecosystem.

Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.

University of Oxford and BIIE launch collaboration in translational immune engineering

Researchers from the Department of Paediatrics at the University of Oxford and the Botnar Institute of Immune Engineering (BIIE) came together in Oxford last week for the inaugural scientific meeting of the new Basel–Oxford Centre for Translational Immune Engineering for Child and Adolescent Health (CTIE). The CTIE is a new collaboration between the Department of Paediatrics and the BIIE in Basel, Switzerland, designed to accelerate the translation of advances in immune engineering into new diagnostics, vaccines, therapeutics and other approaches to prevent and treat disease. Its focus is on improving the health of children and adolescents in low- and middle-income countries.

Oxford-led newborn screening pilot expanded to include all babies in England

Every newborn baby in England will be screened for spinal muscular atrophy (SMA), following the expansion of a pioneering University of Oxford-led pilot that introduced the country’s first routine test for the condition.

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Scientists in the Department of Paediatrics discover antibody combinations that block over 90% of malaria parasite growth

In an important discovery for the next-generation of malaria vaccines, University of Oxford researchers in the Department of Paediatrics, in collaboration with the Scripps Institute, have identified how antibodies can be over 90% effective at preventing malaria parasites from growing in certain combinations.